46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
Titel:
46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
Auteur:
Im, S-A. Tan, A.R. Mattar, A. Colomer, R. Stroyakovskii, D. Nowecki, Z. De Laurentiis, M. Pierga, J-Y. Jung, K.H. Schem, C. Aguila, C. Badovinac Crnjevic, T. Heeson, S. Shivhare, M. Alexandrou, A. Restuccia, E. Jackisch, C.